{"id":12593,"date":"2022-01-10T12:47:28","date_gmt":"2022-01-10T11:47:28","guid":{"rendered":"https:\/\/udic.es\/proyectos-prueba\/"},"modified":"2024-11-19T12:00:21","modified_gmt":"2024-11-19T11:00:21","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/udic.es\/en\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"\t\t\t\t\t\n<h1>Investigational projects.<\/h1>\n<span class=\"s1\"><b>Ongoing Clinical Trials<\/b><\/span>.\t\t\t\t<div class=\"sep\"><\/div>\t\n<div class=\"slogan clearfix  has-button\">\n\t<div class=\"slogan-content\">\n\t\t\n<h1>&#8220;Do you want to participate in our studies?&#8221;<\/h1>\n\t<\/div>\n\t\t<div class=\"button-wrp\">\n\t\t<a href=\"https:\/\/udic.es\/en\/contact\/\" class=\"button vamtam-button accent2  button-filled hover-accent1 \"><span class='icon shortcode  ' style=''>&#57935;<\/span><span class=\"btext\">Explain us<\/span><\/a>\t<\/div>\n\t<\/div>\n\n<div class=\"push\" style='height:13px'><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-2  wpv-first-level first unextended animation-fade-in animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"columna-esquerra\" >\t\t<div class=\"sep-text single centered\">\n\t\t\t\t\t\t\t<span class=\"sep-text-before\"><div class=\"sep-text-line\"><\/div><\/span>\n\t\t\t\t\t\t<div class=\"content\">\n\t\t\t\t<h2 class=\"text-divider-double\">Clinical trials in PARKINSON<\/h2>\t\t\t<\/div>\n\t\t\t<span class=\"sep-text-after\"><div class=\"sep-text-line\"><\/div><\/span>\n\t\t\t\t\t<\/div>\n\t<div class=\"push\" style='height:13px'><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1 caixa-amb-marge first has-background unextended\" style=\"background-color:#5887b9;padding-top:0px;padding-bottom:0px\" id=\"wpv-column-97e8dd9e043cb2693a9e80ebb1b39504\" ><style scoped>#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 p,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 em,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 .column-title,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 .sep-text h2.regular-title-wrapper,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 .text-divider-double,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 .sep-text .sep-text-line,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 .sep,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 .sep-2,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 .sep-3,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 td,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 th,#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504 caption{color:#fff;}#wpv-column-97e8dd9e043cb2693a9e80ebb1b39504:before{background-color:transparent;}<\/style><div class=\"slogan clearfix \">\n\t<div class=\"slogan-content\">\n\t\t\n<strong><span style=\"color: #ffffff;\">Lundbeck: LU18252A:<\/span><br \/>\n<\/strong><span style=\"color: #ffffff;\">Interventional, open-label, exploratory study, investigating the safety, tolerability, pharmacokinetics, and efficacy of Lu AF28996 in patients with Parkinson\u2019s disease.<\/span><strong><br \/>\n<\/strong><\/p>\n<div id=\"gtx-trans\" style=\"position: absolute; left: -76px; top: 1px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>\n\t<\/div>\n\t<\/div>\n<\/div><\/div>\n<div class=\"push\" style='height:13px'><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1 caixa-amb-marge first has-background unextended\" style=\"background-color:#5887b9;padding-top:0px;padding-bottom:0px\" id=\"wpv-column-131eab427fa2a9d6b8942653e952e8fb\" ><style scoped>#wpv-column-131eab427fa2a9d6b8942653e952e8fb p,#wpv-column-131eab427fa2a9d6b8942653e952e8fb em,#wpv-column-131eab427fa2a9d6b8942653e952e8fb .column-title,#wpv-column-131eab427fa2a9d6b8942653e952e8fb .sep-text h2.regular-title-wrapper,#wpv-column-131eab427fa2a9d6b8942653e952e8fb .text-divider-double,#wpv-column-131eab427fa2a9d6b8942653e952e8fb .sep-text .sep-text-line,#wpv-column-131eab427fa2a9d6b8942653e952e8fb .sep,#wpv-column-131eab427fa2a9d6b8942653e952e8fb .sep-2,#wpv-column-131eab427fa2a9d6b8942653e952e8fb .sep-3,#wpv-column-131eab427fa2a9d6b8942653e952e8fb td,#wpv-column-131eab427fa2a9d6b8942653e952e8fb th,#wpv-column-131eab427fa2a9d6b8942653e952e8fb caption{color:#fff;}#wpv-column-131eab427fa2a9d6b8942653e952e8fb:before{background-color:transparent;}<\/style><div class=\"slogan clearfix \">\n\t<div class=\"slogan-content\">\n\t\t\n<strong><span style=\"color: #ffffff;\">BioArctic: BAN0805-201 (EXIST):<\/span><br \/>\n<\/strong><span style=\"color: #ffffff;\">A Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of exidavnemab in patients with mild to moderate Parkinson&#8217;s disease receiving stable medication for symptomatic Parkinson&#8217;s disease.<\/span><strong><br \/>\n<\/strong>\t<\/div>\n\t<\/div>\n<\/div><\/div>\n<div class=\"push\" style='height:13px'><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1 caixa-amb-marge first has-background unextended\" style=\"background-color:#5887b9;padding-top:0px;padding-bottom:0px\" id=\"wpv-column-052420440cf3fc677606933ac3cc0d9c\" ><style scoped>#wpv-column-052420440cf3fc677606933ac3cc0d9c p,#wpv-column-052420440cf3fc677606933ac3cc0d9c em,#wpv-column-052420440cf3fc677606933ac3cc0d9c .column-title,#wpv-column-052420440cf3fc677606933ac3cc0d9c .sep-text h2.regular-title-wrapper,#wpv-column-052420440cf3fc677606933ac3cc0d9c .text-divider-double,#wpv-column-052420440cf3fc677606933ac3cc0d9c .sep-text .sep-text-line,#wpv-column-052420440cf3fc677606933ac3cc0d9c .sep,#wpv-column-052420440cf3fc677606933ac3cc0d9c .sep-2,#wpv-column-052420440cf3fc677606933ac3cc0d9c .sep-3,#wpv-column-052420440cf3fc677606933ac3cc0d9c td,#wpv-column-052420440cf3fc677606933ac3cc0d9c th,#wpv-column-052420440cf3fc677606933ac3cc0d9c caption{color:#fff;}#wpv-column-052420440cf3fc677606933ac3cc0d9c:before{background-color:transparent;}<\/style><div class=\"slogan clearfix \">\n\t<div class=\"slogan-content\">\n\t\t\n<span style=\"color: #ffffff;\"><strong><span class=\"s1\">BIOGEN: 283PD201 (LUMA)<br \/>\n<\/span><\/strong><span class=\"s1\">A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson\u2019s Disease<\/span><\/span><\/p>\n<div id=\"gtx-trans\" style=\"position: absolute; left: 776px; top: 96px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>\n\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div>\n<div class=\"wpv-grid grid-1-2  wpv-first-level unextended animation-fade-in animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-71a5bf6baac59ed157fa4db4a5ba0503\" >\t\t<div class=\"sep-text single centered\">\n\t\t\t\t\t\t\t<span class=\"sep-text-before\"><div class=\"sep-text-line\"><\/div><\/span>\n\t\t\t\t\t\t<div class=\"content\">\n\t\t\t\t<h2 class=\"text-divider-double\">Clinical trials in ALZHEIMER<\/h2>\t\t\t<\/div>\n\t\t\t<span class=\"sep-text-after\"><div class=\"sep-text-line\"><\/div><\/span>\n\t\t\t\t\t<\/div>\n\t<div class=\"push\" style='height:13px'><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1 caixa-amb-marge first has-background unextended\" style=\"background-color:#5887b9;padding-top:0px;padding-bottom:0px\" id=\"wpv-column-2bea2389838e91f02efd3302e1825e97\" ><style scoped>#wpv-column-2bea2389838e91f02efd3302e1825e97 p,#wpv-column-2bea2389838e91f02efd3302e1825e97 em,#wpv-column-2bea2389838e91f02efd3302e1825e97 .column-title,#wpv-column-2bea2389838e91f02efd3302e1825e97 .sep-text h2.regular-title-wrapper,#wpv-column-2bea2389838e91f02efd3302e1825e97 .text-divider-double,#wpv-column-2bea2389838e91f02efd3302e1825e97 .sep-text .sep-text-line,#wpv-column-2bea2389838e91f02efd3302e1825e97 .sep,#wpv-column-2bea2389838e91f02efd3302e1825e97 .sep-2,#wpv-column-2bea2389838e91f02efd3302e1825e97 .sep-3,#wpv-column-2bea2389838e91f02efd3302e1825e97 td,#wpv-column-2bea2389838e91f02efd3302e1825e97 th,#wpv-column-2bea2389838e91f02efd3302e1825e97 caption{color:#fff;}#wpv-column-2bea2389838e91f02efd3302e1825e97:before{background-color:transparent;}<\/style><div class=\"slogan clearfix \">\n\t<div class=\"slogan-content\">\n\t\t\n<span style=\"color: #ffffff;\"><strong>Bristol-Myers Squibb: CN008-003 (TARGET TAU-1):<br \/>\n<\/strong>A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer\u2019s Disease (TargetTau-1).<\/span><strong><br \/>\n<\/strong>\t<\/div>\n\t<\/div>\n<\/div><\/div>\n<div class=\"push\" style='height:13px'><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1 caixa-amb-marge first has-background unextended\" style=\"background-color:#5887b9;padding-top:0px;padding-bottom:0px\" id=\"wpv-column-3e8779d0b2835d02dafc09c4e1ed8679\" ><style scoped>#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 p,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 em,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 .column-title,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 .sep-text h2.regular-title-wrapper,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 .text-divider-double,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 .sep-text .sep-text-line,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 .sep,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 .sep-2,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 .sep-3,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 td,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 th,#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679 caption{color:#fff;}#wpv-column-3e8779d0b2835d02dafc09c4e1ed8679:before{background-color:transparent;}<\/style><div class=\"slogan clearfix \">\n\t<div class=\"slogan-content\">\n\t\t\n<span style=\"color: #ffffff;\"><strong>Acumen: ACU193-201 (ALTITUDE-AD):<\/strong><\/span><br \/>\n<span style=\"color: #ffffff;\">A Phase 2\/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer\u2019s Disease.<\/span><\/p>\n<div id=\"gtx-trans\" style=\"position: absolute; left: -106px; top: 1px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>\n\t<\/div>\n\t<\/div>\n<\/div><\/div>\n<div class=\"push\" style='height:13px'><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1 caixa-amb-marge first has-background unextended\" style=\"background-color:#5887b9;padding-top:0px;padding-bottom:0px\" id=\"wpv-column-2a75720e06205273ab44cfc019d1e82e\" ><style scoped>#wpv-column-2a75720e06205273ab44cfc019d1e82e p,#wpv-column-2a75720e06205273ab44cfc019d1e82e em,#wpv-column-2a75720e06205273ab44cfc019d1e82e .column-title,#wpv-column-2a75720e06205273ab44cfc019d1e82e .sep-text h2.regular-title-wrapper,#wpv-column-2a75720e06205273ab44cfc019d1e82e .text-divider-double,#wpv-column-2a75720e06205273ab44cfc019d1e82e .sep-text .sep-text-line,#wpv-column-2a75720e06205273ab44cfc019d1e82e .sep,#wpv-column-2a75720e06205273ab44cfc019d1e82e .sep-2,#wpv-column-2a75720e06205273ab44cfc019d1e82e .sep-3,#wpv-column-2a75720e06205273ab44cfc019d1e82e td,#wpv-column-2a75720e06205273ab44cfc019d1e82e th,#wpv-column-2a75720e06205273ab44cfc019d1e82e caption{color:#fff;}#wpv-column-2a75720e06205273ab44cfc019d1e82e:before{background-color:transparent;}<\/style><div class=\"slogan clearfix \">\n\t<div class=\"slogan-content\">\n\t\t\n<span style=\"color: #ffffff;\"><strong>Nest\u00e9 Health Sciences: 2302-CLI (COGNIKET-MCI):<\/strong><\/span><br \/>\n<span style=\"color: #ffffff;\">A prospective, randomized, double-blind, placebo-controlled, multi-center, multi-country, pivotal trial to study the effects of a nutritional intervention of ketogenic medium-chain triglycerides (kMCT) and B-vitamins on cognitive functioning in older adults with Mild Cognitive Impairment.<\/span>\t<\/div>\n\t<\/div>\n<\/div><\/div>\n<div class=\"push\" style='height:13px'><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1 caixa-amb-marge first has-background unextended\" style=\"background-color:#5887b9;padding-top:0px;padding-bottom:0px\" id=\"wpv-column-d9acc553222259a58b798d8d9d276cf2\" ><style scoped>#wpv-column-d9acc553222259a58b798d8d9d276cf2 p,#wpv-column-d9acc553222259a58b798d8d9d276cf2 em,#wpv-column-d9acc553222259a58b798d8d9d276cf2 .column-title,#wpv-column-d9acc553222259a58b798d8d9d276cf2 .sep-text h2.regular-title-wrapper,#wpv-column-d9acc553222259a58b798d8d9d276cf2 .text-divider-double,#wpv-column-d9acc553222259a58b798d8d9d276cf2 .sep-text .sep-text-line,#wpv-column-d9acc553222259a58b798d8d9d276cf2 .sep,#wpv-column-d9acc553222259a58b798d8d9d276cf2 .sep-2,#wpv-column-d9acc553222259a58b798d8d9d276cf2 .sep-3,#wpv-column-d9acc553222259a58b798d8d9d276cf2 td,#wpv-column-d9acc553222259a58b798d8d9d276cf2 th,#wpv-column-d9acc553222259a58b798d8d9d276cf2 caption{color:#fff;}#wpv-column-d9acc553222259a58b798d8d9d276cf2:before{background-color:transparent;}<\/style><div class=\"slogan clearfix \">\n\t<div class=\"slogan-content\">\n\t\t\n<span style=\"color: #ffffff;\"><strong>ROCHE: BP42155 (BrainShuttle AD)<\/strong><br \/>\nA randomized, double-blind, placebo-controlled, multiple ascending dose, parallel group study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7126209 after intravenous infusion in patients with prodromal or mild to moderate Alzheimer&#8217;s disease.<\/span>\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div>\n<div class=\"slogan clearfix \">\n\t<div class=\"slogan-content\">\n\t\t\n<h1>Other ongoing studies<\/h1>\n\t<\/div>\n\t<\/div>\n\n<div class=\"row \"><div class=\"wpv-grid grid-1-2  wpv-first-level first unextended animation-from-left animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-df6b0f3be073f38946fdda7e9e0a302a\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode theme ' style='font-size:60px !important;color:#3695EB;'>&#57565;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tParkinson's disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<span style=\"color: #ffffff;\"><br \/>\n<\/span><strong>-ROCHE: BN42358 (PADOVA)<br \/>\n<\/strong>Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson&#8217;s disease.<\/p>\n<p><strong>-NEURODERM: ND0612-007 (BouNDless)<br \/>\n<\/strong> A multicenter, randomized, active-controlled, double-blind, double-masked, parallel-group clinical study to investigate the efficacy, safety, and tolerability of a continuous subcutaneous infusion of ND0612, compared with IR-LD\/CD (immediate\/controlled-release levodopa\/carbidopa) in patients with Parkinson&#8217;s disease who experience motor fluctuations.<\/p>\n<p><strong>-CEREVEL: CVL-751-PD-004 (Tempo-4)<\/strong><br \/>\nA 58-week open-label trial of Tavapadon in Parkinson&#8217;s disease.<\/p>\n<p><strong>-ROCHE: BP39529 (PASADENA)<br \/>\n<\/strong>A 52-week, randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the efficacy of intravenous RO7046015 (PRX002) in participants with early Parkinson&#8217;s disease with a 52-week blind extension.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div>\n<div class=\"wpv-grid grid-1-2  wpv-first-level unextended animation-from-left animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-b22d37ebb9c06541daeccb6f02f77ae4\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode theme ' style='font-size:60px !important;color:#3695EB;'>&#57529;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tAlzheimer\u2019s disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong><span class=\"gmail_default\">-R<\/span>oche: BP 44745 (GABRIELLA):<\/strong><br \/>\nA Phase II, Randomized, Double-blind, Placebo controlled, Multiple dose, Multicenter parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7269162 following Daily oral administration in Participants at Risk for or at the Prodromal stage of Alzheimer\u2019s disease.<\/p>\n<p><strong>-PROTHENA: PRX012-102 (ASCENT-2)<\/strong><br \/>\nPhase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of PRX012 in Subjects with Alzheimer\u2019s Disease.<\/p>\n<p><strong>-ABBVIE: M23-515 (ABRO-AD)<\/strong><br \/>\nA Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-552 in Participants with Mild Alzheimer\u2019s Disease.<\/p>\n<p><strong>-NOVO NORDISK: NN6535-4730 (EVOKE)<\/strong><br \/>\nA phase 3, randomized, double-blind, placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer&#8217;s disease.<\/p>\n<p><strong>-NOVO NORDISK: NN6535-4725 (EVOKE Plus)<br \/>\n<\/strong> A randomized, double-blind, placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer&#8217;s disease.<\/p>\n<p><span style=\"font-family: Arial; font-size: medium;\"><strong>-UCB: AH003 (TOGETHER).<\/strong> Double-blind, patient and investigator, placebo-comparative study to assess the efficacy, safety, and tolerability of bepranemab (UCB0107) in patients with prodromal to mild Alzheimer&#8217;s disease (AD), followed by an open-label run-in. Phase II.<\/span><\/p>\n<p><strong>-JANSSEN: 63733657ALZ2002 (AuTonomy)<br \/>\n<\/strong> A phase 2, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of JNJ-63733657, an anti-Tau monoclonal antibody, in patients with early Alzheimer&#8217;s disease.<\/p>\n<p><strong>-EISAI: BAN2401-G000-301 (CLARITY)<br \/>\n<\/strong>An 18-month, double-blind, parallel-group, placebo-controlled study with an open-label extension phase to confirm the safety and efficacy of BAN2401 in subjects with early Alzheimer&#8217;s disease.<\/p>\n<p><div id=\"attachment_8528\" style=\"width: 5066px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-8528\" class=\"size-full wp-image-8528\" src=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\" alt=\"\" width=\"5056\" height=\"1752\" srcset=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg 5056w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-300x104.jpg 300w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-768x266.jpg 768w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-1024x355.jpg 1024w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-1140x395.jpg 1140w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-555x192.jpg 555w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-360x125.jpg 360w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-262x91.jpg 262w\" sizes=\"auto, (max-width: 5056px) 100vw, 5056px\" \/><\/a><p id=\"caption-attachment-8528\" class=\"wp-caption-text\">Udic<\/p><\/div><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-2  wpv-first-level first unextended animation-from-left animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-b0c13735a6feb9d4815cf80f205aa7c0\" ><div class=\"services clearfix fullimage has-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"137\" src=\"https:\/\/udic.es\/wp-content\/uploads\/2021\/05\/udic1.gif\" class=\"attachment-full size-full\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tOther studies\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>-IMMUNOVANT: IMVT-1401-301 (FLEX)<\/strong><br \/>\nA Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG). IP: <strong>Dr Josep G\u00e1mez.<\/strong><\/p>\n<p><strong><span class=\"gmail_default\">-Noema:\u00a0<\/span>NOE-TTS-201<\/strong><span class=\"gmail_default\"><strong>\u00a0(ALLEVIA-2):<\/strong><br \/>\nA Double-blind, Placebo-controlled, Phase II\/III, Multi-center,\u00a0Twelve-week Prospective Study to Evaluate the Efficacy and\u00a0Safety of Gemlapodect in Adult and Adolescent Patients with\u00a0Tourette Syndrome.<\/span><\/p>\n<p><strong>-ABLIVA: KL1333-2020-104A (FALCON).<\/strong> Adaptive, randomized, double-masked, parallel-group, double-masked, flexible-dose, flexible-dose, placebo-comparative intervention study to evaluate the efficacy of KL 1333 in adult patients with primary mitochondrial disease (PMD). Phase 3. IP:<strong> Dr. Josep G\u00e1mez.<\/strong><\/p>\n<p><strong>-IMMUNOVANT: IMVT-1401-2401:<\/strong> A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). 2023. PI <strong>Dr. Josep G\u00e1mez.<\/strong> Hospital Universitari General de Catalunya. Fase 2b.<\/p>\n<div id=\"gtx-trans\" style=\"position: absolute; left: 571px; top: 265px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>\n<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div>\n<div class=\"wpv-grid grid-1-2  wpv-first-level unextended animation-from-left animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-6cdcb8a9d49676449216ececce1b3a12\" ><div class=\"services clearfix fullimage has-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"137\" src=\"https:\/\/udic.es\/wp-content\/uploads\/2021\/05\/udicgif2.gif\" class=\"attachment-full size-full\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tUncoming projects...\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>-ROCHE: Trontinemab phase 3.<\/strong> WN 45443. A phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group efficacy and safety study of Trontinemab in patients with early Alzheimer&#8217;s disease (MCI to mild Dementia due to AD).<\/p>\n<p><strong>-DENALI: DNLI-C-0009.<\/strong> A Phase 2a, Multicenter, Randomized, Double-Blind,\u00a0Placebo-Controlled Study to Evaluate the Safety and\u00a0Pharmacodynamic Effects of BIIB122 in Participants With\u00a0LRRK2-Associated Parkinson\u2019s Disease (LRRK2-PD).<\/p>\n<p><strong>-Janssen: 64042056ALZ2001 (RETAIN):<br \/>\n<\/strong>A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer\u2019s Disease.<\/p>\n<div id=\"gtx-trans\" style=\"position: absolute; left: 223px; top: 1px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>\n<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n\t\t<h2 class=\"text-divider-double\">\t\t\t\nClinical trial history\t\t<\/h2>\t\t<div class=\"sep\"><\/div>\t\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-c2246342bb7b69e91769984709522e3f\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57588;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tParkinson's disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong><span class=\"s1\">\u2013 <\/span>CVL-751-PD-001 (TempPo-1)<\/strong><br \/>\nA 27-week, double-blind, randomized, placebo-controlled, parallel-group, phase 3 trial of the efficacy, safety, and tolerability of two fixed-dose tavapadon in early Parkinson\u2019s disease.<\/p>\n<p><strong><span class=\"s1\">\u2013 <\/span>ANNOVIS: ANVS-22001<\/strong><br \/>\nA 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of buntanetap or placebo in patients with early Parkinson\u2019s disease.<\/p>\n<p><strong><span class=\"s1\">\u2013 <\/span>SUN PHARMA: SPARC CRL18-06 (PROSEEK)<\/strong><br \/>\nA phase 2, randomized, double-blind, placebo-controlled study of K0706 in patients with early Parkinson\u2019s disease to evaluate the safety and efficacy of tyrosine kinase inhibition of Abl.<\/p>\n<p><strong><span class=\"s1\">\u2013 <\/span>CVL-751-PD-001 (TempPo-3)<br \/>\n<\/strong>A Phase 3, double-blind, randomized, placebo-controlled, parallel-group, flexible-dose, 27-week trial to evaluate the efficacy, safety, and tolerability of tavapadon as add-on therapy for Parkinson\u2019s disease in adults with motor fluctuations treated with levodopa.<\/p>\n<p><strong><span class=\"s1\">\u2013 <\/span>BIOGEN: 254PD101 (REASON)<br \/>\n<\/strong>A Phase 1 Single, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults with Parkinson\u2019s Disease.<\/p>\n<p><strong><span class=\"s1\">\u2013 <\/span>CONTERA: JM010-CS03 (ASTORIA)<br \/>\n<\/strong>Randomized, double-blind, placebo-controlled, parallel-group study in Parkinson\u2019s disease patients with moderate to severe dyskinesia to evaluate the efficacy, safety, and tolerability of two dose combinations of JM-010.<\/p>\n<p><strong><span class=\"s1\">\u2013 BIOGEN: 283PD302 (LIGHTHOUSE)<br \/>\n<\/span><\/strong><span class=\"s1\">A phase 3, multicenter, randomized, double-blind, placebo controlled study to determine the efficacy and safety of biib122\/dnl151 in participants with parkinson&#8217;s disease \u00a0and pathogenic lrrk2 variants<\/span><\/p>\n<p><strong>\u2013 CTH-301.<\/strong> An open label extension study with sublingual apomorphine to assess its long-term safety (for 3 years) in fluctuating Parkinsonian patients.<\/p>\n<p><strong>\u2013 PHARMA TWO 2:<\/strong> P2B001-003. A Phase 3, twelve-week, multicenter, multinational, randomized, double-blind, double-dummy, parallel-group study to determine the efficacy, safety, and tolerability of once-daily P2B001 compared to its individual components in subjects with Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 IMPAX:<\/strong> IPX203-B16-03. An open-label extension to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson&#8217;s disease patients with motor fluctuations.<\/p>\n<p><strong>\u2013 IMPAX:<\/strong> IPX203-B16-02 (RISE-PD). Randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in patients with Parkinson&#8217;s disease and motor fluctuations.<\/p>\n<p><strong>\u2013 SUNOVION:<\/strong> CTH-302. An open-label, randomized, crossover trial using a single-blind rater to evaluate APL-130277 compared with subcutaneous Apomorphine in levodopa-responsive subjects in complicated Parkinson&#8217;s disease with motor fluctuations.<\/p>\n<p><strong>\u2013 BIOGEN:<\/strong> 228PD201 (SPARK). A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of BIIB037 in subjects with early symptomatic Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 PREXTON:<\/strong> PXT-CL17-001 ( AMBLED). A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 28-Day Oral Treatment with PXT002331 to Reduce Motor Complications of Levodopa Treatment in Patients with Parkinson&#8217;s Disease experiencing end-dose fading and levodopa-induced dyskinesia.<\/p>\n<p><strong>\u2013 INTEC PHARMA:<\/strong> IN11004 and IN11004E. A phase III, multicenter, randomized, double-blind, double-dummy, active-controlled study to compare the efficacy and safety of the gastric retention tablet and controlled release (accordion pills) carbidopa\/ levodopa (AP-CD\/LD) and immediate-release CD\/LD in patients with fluctuating Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 BIOTIE\/ACORDA:<\/strong> TOZ CL-05. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson&#8217;s Disease Experiencing End-of-Dose \u201cWearing -Off.<\/p>\n<p><strong>\u2013 CIVITAS\/ACORDA:<\/strong> CVT-301-004 (SPAN-PD). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson&#8217;s Disease Patients With Motor Response Fluctuations (OFF Phenomena).<\/p>\n<p><strong>\u2013 CIVITAS\/ACORDA:<\/strong> CVT 301-005. Randomized study to investigate the safety and effect of CVT301 (inhaled Levodopa) compared to standard treatment for Parkinson&#8217;s disease with motor fluctuations (off).<\/p>\n<p><strong>\u2013 OSMOTICA:<\/strong> OS320-3006 (ALLAYD-II). Multicenter, randomized, placebo-controlled, double-blind trial to evaluate the efficacy and safety of &#8220;extended release&#8221; amantadine for 26 weeks in Parkinson&#8217;s disease with levodopa-induced dyskinesias.<\/p>\n<p><strong>\u2013 OSMOTIC:<\/strong> OS320-3005 (ALLAYD-I). Multicenter, randomized, placebo-controlled, double-blind trial to evaluate the efficacy and safety of &#8220;extended release&#8221; amantadine for 16 weeks in Parkinson&#8217;s disease with levodopa-induced dyskinesias.<\/p>\n<p><strong>\u2013 BIAL:<\/strong> BIA 91067-301. A Phase III Study to evaluate Efficacy and Safety of BIA 91067-301 in patients with Idiopathic Parkinson&#8217;s disease with Wearing Off phenomenon treated with Levodopa and a Dopa decarboxylase inhibitor (IDDC) by means a multicenter clinical trial, double-blind, randomized active and placebo controlled, parallel group trial.<\/p>\n<p><strong>\u2013 MUNDIPHARMA:<\/strong> OXN 2504. Phase III, multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and tolerability of OXN PR for the treatment of severe pain associated with Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> CAFQ056 A2299. Phase II\/III study of open treatment to evaluate the safety, tolerability and efficacy of AFQ056 in levodopa-induced dyskinesias in patients with Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> CAFQ056 A2223. Phase II double-blind, placebo-controlled, fixed-dose, multicenter, 13-week follow-up study to evaluate the efficacy and safety of modified-release AFQ056 in reducing moderate to severe levodopa-induced dyskinesias in patients with Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> CAFQ056 A2222. Phase II, double-blind, placebo-controlled, fixed-dose, multicenter, 12-week follow-up study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe levodopa-induced dyskinesias in patients with Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 MERCK SCHERING PLOUGH:<\/strong> P05664. Phase 3, double-blind, placebo- and active-controlled, range-finding, efficacy and safety study of Preladenant in subjects with early Parkinson&#8217;s disease. PI: Dr. E. Balaguer, at General Hospital of Catalonia &amp; PI: Dr. A. Ugarte, at Sant Joan de D\u00e9u Hospital, Manresa.<\/p>\n<p><strong>\u2013 MERCK SCHERING PLOUGH:<\/strong> P06153. Phase III active-controlled, double-blind, double-dummy extension study of Preladenant in subjects with moderate to severe Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 MERCK SCHERING PLOUGH:<\/strong> P04938. A 12-week, double-blind, placebo- and active-controlled phase 3 efficacy and safety study of Preladenant in subjects with moderate to severe Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 SCHWARZ BIOSCIENCES \/ UCB:<\/strong> SP1066. A multicenter, phase I, randomized, double-blind, two-way cross-over study to compare the adhesiveness of two different Rotigotine patch formulations in subjects with Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 MERCK SERONO:<\/strong> OLE28850. Open-label Phase III study to determine the long-term safety of safinamide in patients with Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 MERCK SERONO:<\/strong> EMR 701165-024. Phase II, double-blind, randomized, placebo-controlled, parallel-group study to explore the possible beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson&#8217;s disease (PD) and cognitive impairment.<\/p>\n<p><strong>\u2013 IMPAX Pharmaceuticals:<\/strong> IPX066-B09-03. Study to evaluate the safety and efficacy of IPX066 in advanced Parkinson&#8217;s disease. An open label extension.<\/p>\n<p><strong>\u2013 IMPAX Pharmaceuticals:<\/strong> IPX066-B09-02. A phase III study to evaluate the safety and efficacy of IPX066 in advanced Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> CAFQ056A2208. Multicenter, double-blind, placebo-controlled, fixed-dose, 13-week study to evaluate the efficacy and safety of AFQQ056 in reducing moderate and severe levodopa-induced dyskinesias in patients with Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 ACADIA:<\/strong> ACP-103-014. A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson&#8217;s Disease.<\/p>\n<p><strong>\u2013 BOEHRINGER-INGELHEIM:<\/strong> BI 248.634. Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson&#8217;s disease (PD).<\/p>\n<p><strong>\u2013 BOEHRINGER-INGELHEIM:<\/strong> BI 248,525. Randomized, double-blind, double-blind, placebo-controlled, 3-parallel-group study to compare the efficacy, safety, and tolerability of Pramipexole ER versus placebo and Pramipexole IR, administered orally during a 26-week maintenance phase in patients with advanced Parkinson&#8217;s disease treated with levodopa.<\/p>\n<p><strong>\u2013 SCHWARZ PHARMA:<\/strong> SP 873. International, \u201cproof of concept\u201d clinical trial to assess the efficacy and safety of Rotigotine, administered intranasally in advanced Parkinson&#8217;s disease with motor fluctuations and dyskinesias.<\/p>\n<p><strong>\u2013 SCHWARZ PHARMA:<\/strong> SP 833. Multicenter, open-label extension clinical trial to assess the efficacy, tolerance and safety of Rotigotine, administered in subcutaneous patches, in patients with initial Parkinson&#8217;s disease and sleep disorders.<\/p>\n<p><strong>\u2013 SCHWARZ PHARMA:<\/strong> SP 825. Ropinirole-controlled, randomized, multicenter clinical trial to evaluate the efficacy, tolerance and safety of Rotigotine, administered in subcutaneous patches, in patients with initial Parkinson&#8217;s disease and sleep disorders.<\/p>\n<p><strong>\u2013 SCHWARZ PHARMA:<\/strong> SP 516. Multicenter, open-label extension clinical trial to assess the efficacy, tolerance and safety of Rotigotine, administered in subcutaneous patches, in patients with advanced Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 SCHWARZ PHARMA:<\/strong> SP 515. Multicenter, randomized, double-blind, placebo- and Pramipexole-controlled clinical trial to evaluate the efficacy, tolerance and safety of Rotigotine, administered in subcutaneous patches, in patients with advanced Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> CENA 713-IA 05. Prospective, multicenter, randomized, double-blind, placebo-controlled and parallel group study of 24 weeks duration, to test the efficacy, tolerability and safety of 3-12 mg\/day of Exelon (Rivastigmine) in capsules, in patients with probable vascular dementia.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> 713-B2311 E1 (DINNER). Clinical Trial 24-Week Open-Label Extension Study: A 24-week, prospective, randomized, double-blind, parallel, placebo-controlled, multicenter study to assess the efficacy, tolerability, and safety of 3-12 mg\/ day of Exelon (Rivastigmine) in capsules, in patients with dementia due to Parkinson&#8217;s Disease.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> DINNER 713-B2311. Multicenter, prospective, randomized, double-blind, parallel and placebo controlled study, of 24 weeks duration, to evaluate the efficacy, tolerability and safety of 3-12 mg\/day of Exelon (Rivastigmine) in capsules, in patients with dementia due to Parkinson&#8217;s disease.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> CCOM998 IA04. Multicenter, open-label study to evaluate different dose regimens of the combination levodopa \/ DDCI \/ entacapone, in patients with Parkinson&#8217;s disease who begin to experience symptoms of end-of-dose deterioration.<\/p>\n<p><strong>\u2013 SCHERING AG:<\/strong> Continuous subcutaneous administration (12h\/24h) in advanced Parkinson&#8217;s disease with complex fluctuations and dyskinesias, by Lisuride subcutaneous infusion pump. 1987-1988. Research collaborator. Principal investigator Dr. E. Tolosa. Hospital Clinic (Barcelona). Phase II (proof of concept).<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-2218187e2da841b97abe092c192ad8cc\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57578;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tAlzheimer disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013EISAI: BAN2401-G000-201 OLE<br \/>\n<\/strong>A Double-Blind, Parallel-Group, Placebo-Controlled, Bayesian Adaptive Randomization Design, Dose Regimen-Searching Study with an Open-Label Extension Phase to Evaluate the Safety, Tolerability, and Efficacy of BAN2401 in Subjects with Early Alzheimer\u2019s Disease.<\/p>\n<p><strong>\u2013LILLY: J1G-MC-LAKD. (TRAILRUNNER-ALZ 2). <\/strong>Assessment of safety and efficacy of subcutaneous remternetug in early symptomatic Alzheimer\u2019s disease. Compound: Remternetug (LY3372993). Study Phase: 3.<\/p>\n<p><strong>\u2013BIAL: BIA 28-6156-201.<\/strong> A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIA 28 6156 in Subjects With Parkinson\u2019s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene.<\/p>\n<p><strong>\u2013NEURIMMUNE: NI004-201. <\/strong>A phase 1b\/2a, multicenter, randomized, parallel group, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of M1 (ortosteric selective) muscarinic agonist NI004 compared to placebo in mild Alzheimer&#8217;s disease to moderate.<\/p>\n<p><strong>\u2013ABBVIE: M22-721 (HARBOR)<\/strong><br \/>\nProtocol for Study M22-721 Alzheimer\u2019s Disease: A Phase 1b\/2a Multiple Ascending Dose and Proof-of-Concept Study of ABBV-916.<\/p>\n<p><strong>\u2013AVANIR: 20-AVP-786-307 (ASPECT)<\/strong><br \/>\nA phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide \/quinidine sulfate) for the treatment of agitation in patients with dementia of the Alzheimer type.<\/p>\n<p><strong>\u2013TauRx Therapeutics: TRx-237-039 (LUCIDITY).<br \/>\n<\/strong>A 9-month, three-arm, randomized, double-blind, placebo-controlled study of brain imaging and the safety and efficacy of LMTM in subjects with early Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013ROCHE: WN29922 (GRADUATE).<br \/>\n<\/strong>A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of gantenerumab in patients with early Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013CORTEXYME:<\/strong> COR388-010 (GAIN). A randomized, double-blind, placebo-controlled study of COR388HCI in subjects with Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 ACADIA:<\/strong> ACP-103-045. A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis.<\/p>\n<p><strong>\u2013 BOEHRINGER-INGELHEIM:<\/strong> 1346.23 A multi-centre, double-blind, parallel-group, randomized controlled study to investigate efficacy, safety and tolerability of orally administered BI 425809 during a 12-week treatment period compared to placebo in patients with cognitive impairment due to Alzheimer&#8217;s Disease. PI: Dr. E. Balaguer. General University Hospital of Catalonia. PI: Dr. A. Hern\u00e1ndez. Sant Joan de D\u00e9u Hospital, Manresa.<\/p>\n<p><strong>\u2013 EISAI:<\/strong> E2609-G000-301 (MISSION AD). A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer&#8217;s Disease.<\/p>\n<p><strong>\u2013 HEPTARES.<\/strong> HTL0018318-202. A phase 1b randomized, double-blind, placebo-controlled, parallel group, multi-center study to determine the safety and tolerability of HTL0018318 in subjects with mild to moderate Alzheimer&#8217;s disease receiving donepezil or donepezil \/ memantine.<\/p>\n<p><strong>\u2013 JANSSEN:<\/strong> 54861911ALZ2003 (EARLY). A phase II b \/ III randomized, double-blind, placebo-controlled, parallel group, multicenter study investigating the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer&#8217;s Dementia. PI: Dr. A. Ugarte. Sant Joan de D\u00e9u Hospital, Manresa.<\/p>\n<p><strong>\u2013 AXOVANT:<\/strong> RVT-101-3002. Open Label extension of a phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 AXOVANT:<\/strong> RVT-101-3001. A Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 ROCHE:<\/strong> BN40031 (CREAD OLE). Multicenter, open-label, long-term extension study of Phase III studies (BN29552\/BN29553) of Crenezumab (RO5490245) in patients with mild Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 ROCHE:<\/strong> BN 29553 (CREAD2). Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Crenezumab (RO5490245) in patients with mild Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 ROCHE:<\/strong> BN 29552 (CREAD). Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Crenezumab (RO5490245) in patients with mild Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 BIOGEN:<\/strong> 221AD301 (EMERGE). Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Patients With Early Alzheimer&#8217;s Disease. PI: Dr. A. Ugarte. Sant Joan de D\u00e9u Hospital, Manresa.<\/p>\n<p><strong>\u2013 LILLY\/ASTRAZENECA:<\/strong> I8D-MC-AZET (DAYBREAK). Randomized, double-blind, placebo-controlled, delayed-start study of LY3314814\/AZD3293 in mild Alzheimer&#8217;s disease dementia.<\/p>\n<p><strong>\u2013 ASTRAZENECA\/LILLY:<\/strong> AZD3293 (AMARANTH). A 24-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, tolerability, biomarkers, and pharmacokinetics of AZD3293\/LY3314814 in early-stage Alzheimer&#8217;s disease. 2015-2017. PI: Dr. A. Ugarte. Sant Joan de D\u00e9u Hospital, Manresa.<\/p>\n<p><strong>\u2013 BOEHRINGER INGELHEIM:<\/strong> 1289.5. Multicenter, double-blind, randomized controlled parallel group study to investigate the efficacy, safety, and tolerability of BI 409306, administered orally over a 12-week treatment period, compared to placebo in patients with Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 LILLY:<\/strong> H8A-MC-LZAX. Effect of passive immunization on the progression of mild Alzheimer&#8217;s disease Solanezumab (LY2062430) versus placebo. PI: Dr. A. Ugarte. Sant Joan de D\u00e9u Hospital, Manresa.<\/p>\n<p><strong>\u2013 GRIFOLS:<\/strong> IG1002 (AMBER). Multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmapheresis with infusions of human albumin combined with intravenous immunoglobulin in patients with mild-moderate Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 LUNDBECK:<\/strong> LU14863. Phase 3, multicenter, randomized, double-blind, comparative, placebo-controlled, parallel-group clinical study to evaluate the efficacy and safety of Lu AE58054 in patients with mild-to-moderate Alzheimer&#8217;s disease treated with acetylcholinesterase inhibitors. PI: Dr. A. Ugarte. Sant Joan de D\u00e9u Hospital, Manresa. PI: Dr. E. Balaguer. General Hospital of Catalonia.<\/p>\n<p><strong>\u2013 LUNDBECK:<\/strong> LU14861B \/ Memantine. Open and Memantine Extension of Trial 14861A. 2015-2016. Collaborating researcher. PI: Dr. A. Ugarte. Sant Joan de D\u00e9u Hospital, Manresa. PI: Dr. E. Balaguer. General Hospital of Catalonia.<\/p>\n<p><strong>\u2013 LUNDBECK:<\/strong> LU14861A. Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE 58054 in patients with mild or moderate Alzheimer&#8217;s disease treated with Donepezil. PI: Dr. A. Ugarte. Sant Joan de D\u00e9u Hospital, Manresa. PI: Dr. E. Balaguer. General Hospital of Catalonia.<\/p>\n<p><strong>\u2013 LUPIN:<\/strong> LRP\/LND101001. A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with Mild to Moderate Alzheimer&#8217;s Disease.<\/p>\n<p><strong>\u2013 EISAI:<\/strong> BAN2401-G000-201. Bayesian adaptive randomization, double-blind, parallel-group, placebo-controlled dosage regimen study to evaluate the safety, tolerability, and efficacy of BAN2401 in subjects with early-onset Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 SERVIER:<\/strong> CL2-38093-012. Phase IIb, multicenter, randomized study to investigate the efficacy and safety of 3 doses of S38093 (2, 5 and 20 mg\/day) versus placebo, associated with Donezepil (10 mg\/day) in patients with moderate Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 ROCHE:<\/strong> BP 28248. Phase III, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the efficacy and safety of RO4602522 added to background treatment with acetylcholinesterase inhibitors, Donezepil or Rivastigmine, in patients with moderate-intensity Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 GENENTECH\/ROCHE:<\/strong> GN 28525. Open-label extension study to evaluate the efficacy and safety of MABT5102A in patients with mild or moderate Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 LILLY:<\/strong> 140-MC-BACC. Evaluation of the safety, tolerability, and pharmacodynamic effects of LY2886721 in patients with mild cognitive impairment due to Alzheimer&#8217;s disease or with mild Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 GENENTECH\/ROCHE:<\/strong> GN ABE 4869g. Multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the efficacy and safety of MABT5102A in patients with mild to moderate Alzheimer&#8217;s disease.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> CAD106 A2203. Multicenter, randomized, double-blind, placebo-controlled, 90-week, adaptive-design clinical trial in patients with mild Alzheimer&#8217;s disease to investigate the safety, tolerability, and response of specific anti-AB antibodies after repeated intramuscular administration of CAD106 with adjuvant.<\/p>\n<p><strong>\u2013 GSK:<\/strong> AVA 105640. A 36-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE \u03b54-stratified subjects with mild to moderate Alzheimer&#8217;s disease. PI: Dr. L. Soler. General Hospital of Catalonia.<\/p>\n<p><strong>\u2013 NOVARTIS:<\/strong> CENA713-ES-02. Pilot, multicenter, randomized, double-blind, controlled, parallel study to evaluate the efficacy and safety of Rivastigmine versus placebo in the treatment of cognitive and non-cognitive symptoms in patients with moderate-severe Alzheimer&#8217;s disease.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-b22b1513f4588cae6677857708ba7183\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57603;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tProgressive Supranuclear Palsy\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 Alfa Bioresearch:<\/strong> AB 13004. A prospective, multicenter, randomized, double-blind, placebo-controlled, parallels groups phase IIb \/ III study to compare the efficacy and safety of Masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy.<\/p>\n<p><strong>\u2013 BRISTOL MYERS SQUIB\/BIOGEN. CN 002-012 \/ 251PP301 (PASSPORT).<\/strong> Randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of intravenously administered BMS 986168 in patients with Progressive Supranuclear Palsy with an open extension.<\/p>\n<p><strong>\u2013 UCB: PSP003.<\/strong> A Participant-Blind, Investigatir Blind, Placebo-Controlled, Phase IB Study to evaluate the safety, tolerability, and pharmacokinetics of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-4b8acc1aa114f67ea64d37133bb7525a\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57607;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tX fragile syndrome\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 NOVARTIS: CAFQ056-A2212.<\/strong> Double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of AFQ056 in adult patients with Fragile Syndrome.<\/p>\n<p><strong>\u2013 NOVARTIS: CAFQ056-B2214.<\/strong> Double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome.<\/p>\n<p><strong>\u2013 NOVARTIS: CAFQ056-B2279.<\/strong> Open-label extension study to evaluate the safety, efficacy, and tolerability of AFQ056 in adult patients with Fragile X Syndrome.<\/p>\n<p><strong>\u2013 NOVARTIS: CAFQ056-B2278.<\/strong> Open-label extension study to evaluate the safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome.<\/p>\n<p><strong>\u2013 NOVARTIS CAFQ056-B2154.<\/strong> A sequential phase I with 2 periods to evaluate the pharmacokinetics, safety and tolerability of an oral single dose or multiple oral doses of AFQ056 in patients with Fragile X Syndrome, between 5 and 11 years of age (Cohort 1) and between 3 and 4 years of age (Cohort 2).<\/p>\n<p><strong>\u2013 ROCHE: NP27936.<\/strong> Phase II, randomized, double-blind, placebo-controlled parallel group study to investigate the efficacy and safety of RO4917523 in patients with Fragile X Syndrome.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-06a0864077d13db2277e404a2bd86e68\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57602;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tMultiple sclerosis\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 NURON: NU-100-101.<\/strong> Phase III multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis<\/p>\n<p><strong>\u2013 NOVARTIS: CFTY 720 D2402.<\/strong> Phase II, double-blind, randomized, double-blind, multicenter study of parallel groups that studies the structural changes in the retina and the evolution of visual function after immediate versus delayed treatment with fingolimod in patients with acute demelianizing optic neuritis.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-3a78a1d03126e69801dfd4b36c3b38e1\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57592;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tEpilepsy\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 BIAL: IMDYVA study (Impact of Depression and quality of Life).<\/strong> Epidemiological study of depression in patients with focal epilepsy and its impact on quality of life.<\/p>\n<p><strong>\u2013 BIAL: BIA 2093-311.<\/strong> Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Newly Diagnosed Patients with Partial-Onset Seizures: Double-Blind, Randomized, Active-Drug, Parallel-Group, Multicenter Study. PI: Dr. E. Balaguer. General Hospital of Catalonia. PI: Dr A. Ugarte. Hospital Sant Joan de D\u00e9u, Manresa, Fundaci\u00f3 Althaia.<\/p>\n<p><strong>\u2013 UCB: SP 0980.<\/strong> Efficacy and Safety of Lacosamide in drug-resistant epilepsy. PI: Dr A. Ugarte. Hospital Sant Joan de D\u00e9u, Manresa, Fundaci\u00f3 Althaia.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-00ef62e0be8d2b1051286855d1000c88\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57586;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tCerebral vascular disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 ASTRA: CLASS (Clomethiazol Acute Stroke Study)<\/strong>. Neuroprotection with clomethiazole, double-blind, placebo-control, in acute stroke, from 6 to 12 hours of evolution. PI: Dr. L. Soler. General Hospital of Catalonia.<\/p>\n<p><strong>\u2013 URIACH: TACIP.<\/strong> Trifusal versus acetylsalicylic acid in the secondary prevention of ischemic stroke. PI: Dr. L. Soler. General Hospital of Catalonia.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-d316bf811ae6b0f0be713faebfc9bc71\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57586;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tRestless Leg Syndrome\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 BOEHRINGER-INGELHEIM:<\/strong> BI 248.604. Randomized study to evaluate the efficacy and safety of pramipexole versus placebo in restless legs syndrome and mood disorders.<\/p>\n<p><strong>\u2013 BOEHRINGER-INGELHEIM:<\/strong> BI 248.615. Randomized study to evaluate the efficacy and safety of Pramipexole versus placebo in restless legs syndrome and sleep disturbance.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-e2e2781447ed6e11aaf27c9e8ff8f88c\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57586;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tTourette s\u00edndrome\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 BOEHRINGER-INGELHEIM: BI 248.641.<\/strong> A Phase III double-blind, double-dummy, placebo-controlled, 8-week fixed-dose trial with pramipexole IR 0.125 and 0.5 mg\/day administered orally to investigate the efficacy and safety in patients 6-17 years of age diagnosed with Tourette Syndrome according to DSM-IV criteria.<\/p>\n<p><strong>\u2013 OTSUKA: 12-31-293.<\/strong> Multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of aripiprazole administered in fixed doses orally once daily in children and adolescents with Gilles de la Tourette syndrome.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-8207ddacca3c1636f3c20b9d5c28fae2\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57586;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tNon-neurological clinical trials\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 COSMO\/CROSS: CRO-16-130 S (CB-01-11\/28).<\/strong> A Phase II, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study of the efficacy and safety of Rifamycin SV-MMX\u00ae 600 mg tablets administered three or twice daily to patients with bowel syndrome irritable with predominant diarrhea. PI: Dr. E. Saperas. General Hospital of Catalonia.<\/p>\n<p><strong>\u2013 LEON FARMA:<\/strong> CF 111\/302. Phase III pivotal, multicenter, double-blind, double-masked, randomized study to compare the contraceptive efficacy, tolerability and safety of LF111 (Drospirenone) for 9 cycles with Cerazette (Desogestrel 0.075 mg). November 2012- June 2013. Collaborating researcher and management. General Hospital of Catalonia.<\/p>\n<p><strong>\u2013NOVARTIS:<\/strong> CLCZ696B2320 (PERSPECTIVE). Multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to Valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction. General Hospital of Catalonia.<\/p>\n<p class=\"p1\"><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"push\" style='height:30px'><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-12593","page","type-page","status-publish"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Clinical Trials - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Trials - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-19T11:00:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"5056\" \/>\n\t<meta property=\"og:image:height\" content=\"1752\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"23 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/clinical-trials\/\",\"url\":\"https:\/\/udic.es\/en\/clinical-trials\/\",\"name\":\"Clinical Trials - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/clinical-trials\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/clinical-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\",\"datePublished\":\"2022-01-10T11:47:28+00:00\",\"dateModified\":\"2024-11-19T11:00:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/clinical-trials\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/clinical-trials\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/clinical-trials\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/clinical-trials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Trials - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Trials - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_url":"https:\/\/udic.es\/en\/clinical-trials\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_modified_time":"2024-11-19T11:00:21+00:00","og_image":[{"width":5056,"height":1752,"url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"23 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/clinical-trials\/","url":"https:\/\/udic.es\/en\/clinical-trials\/","name":"Clinical Trials - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg","datePublished":"2022-01-10T11:47:28+00:00","dateModified":"2024-11-19T11:00:21+00:00","breadcrumb":{"@id":"https:\/\/udic.es\/en\/clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/clinical-trials\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/pages\/12593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=12593"}],"version-history":[{"count":122,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/pages\/12593\/revisions"}],"predecessor-version":[{"id":18376,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/pages\/12593\/revisions\/18376"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=12593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}